Biopharmaceutical company Medivation (MDVN) recently turned profitable in a big way. The company — a new entrant to the IBD Stock Spotlight screen — focuses on developing therapies to treat serious illnesses for which few treatment options exist. On Nov. 6, Medivation reported third-quarter earnings of 96 cents a share compared with a loss in the year-earlier period. Sales growth accelerated for a second straight quarter to a 234% gain.